Jianchun Duan

9PUBLICATIONS
64CO-AUTHORS
Molecular targetsInnate immunityEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersAvionics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Feb 08, 2024
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy.

Jiefei Han, Yiting Dong, Xiuli Zhu

|Oct 14, 2023
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC.

Yiyi Huang, Yi-Fung Chau, Hua Bai

|Apr 07, 2023
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors.

Boyang Sun, Tian Qiu, Xiaoling Zeng

|Nov 26, 2022
Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer.

Yiting Dong, Yixiang Zhu, Minglei Zhuo

|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.

Shun Lu, Xiaorong Dong, Hong Jian

Pageof 2

Frequent Collaborators

6 joint publications

Jie Wang

5 joint publications

Zhijie Wang

4 joint publications

Jiachen Xu

3 joint publications

Jiefei Han